Arcutis Biotherapeutics (ARQT) Total Current Liabilities (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Total Current Liabilities of $163.2 million for Q1 2026, up 79.09% year-over-year from $91.1 million in Q1 2025, and up 25.7% quarter-over-quarter from $129.8 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Total Current Liabilities (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $163.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 79.09% year-over-year to $163.2 million; the TTM figure through Mar 2026 stood at $163.2 million (up 79.09% YoY), while the FY2025 annual figure was $129.8 million, up 60.27% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $163.2 million, up from $129.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $172.4 million in Q3 2024, with the low at $27.5 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $47.3 million (2024), against an average of $72.8 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 311.63% in 2024, then sank 42.14% in 2025.
- Arcutis Biotherapeutics' Total Current Liabilities stood at $37.8 million in 2022, then increased by 23.44% to $46.7 million in 2023, then jumped by 73.59% to $81.0 million in 2024, then jumped by 60.27% to $129.8 million in 2025, then rose by 25.7% to $163.2 million in 2026.
- Business Quant data shows ARQT's Total Current Liabilities at $163.2 million in Q1 2026, $129.8 million in Q4 2025, and $99.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 160.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.34 Mn |
| Mar 31, 2026 | 163.20 Mn |
| Dec 31, 2025 | 129.84 Mn |
| Sep 30, 2025 | 99.77 Mn |
| Jun 30, 2025 | 103.94 Mn |
| Mar 31, 2025 | 91.13 Mn |
| Dec 31, 2024 | 81.01 Mn |
| Sep 30, 2024 | 172.43 Mn |
| Jun 30, 2024 | 51.35 Mn |
| Mar 31, 2024 | 47.31 Mn |
| Dec 31, 2023 | 46.67 Mn |
| Sep 30, 2023 | 41.89 Mn |
| Jun 30, 2023 | 36.66 Mn |
| Mar 31, 2023 | 37.03 Mn |
| Dec 31, 2022 | 37.81 Mn |
| Sep 30, 2022 | 37.10 Mn |
| Jun 30, 2022 | 27.48 Mn |
| Mar 31, 2022 | 32.96 Mn |
| Dec 31, 2021 | 33.33 Mn |
| Sep 30, 2021 | 19.06 Mn |